Table 2 Risk factor analysis for in-hospital death in high risk patients (EA ≥ 0.54 at T0) and in low risk patients (EA < 0.54 at T0).

From: Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study

 

Univariate analysis

Multivariate analysis

OR (95% CI)

p value

OR (95% CI)

p value

In high risk patients (EA at T0 ≥ 0.54)

PMX-HP treatment

0.53 (0.13–2.20)

0.18

0.04 (0.01–0.71)

0.03

Age (years)

1.01 (0.94–1.08)

0.76

  

APACHE II at admission

1.01 (0.93–1.09)

0.83

  

SOFA score at T0

1.24 (1.03–1.49)

0.02

1.56 (1.13–2.16)

0.007

Duration of surgery (min)

1.01 (0.99–1.01)

0.47

  

In low risk patients (EA at T0 < 0.54)

PMX-HP treatment

4.00 (0.45–35.79)

0.22

  

Age (years)

1.03 (0.94–1.13)

0.54

  

APACHE II at admission

1.16 (0.99–1.36)

0.055

  

SOFA score at T0

1.28 (1.00–1.64)

0.047

1.28 (1.00–1.64)

0.047

Duration of surgery (min)

0.98 (0.96–1.00)

0.078

  
  1. APACHE Acute physiology and Chronic Health Evaluation, CI confidence interval, EA Endotoxin activity, OR Odd ratio, PMX-HP Polymyxin B-hemoperfusion, SOFA Sequential Organ Failure Assessment.
  2. Significant values are in [italics].
Back to article page